Technical Analysis for CYYNF - Cynata Therapeutics Ltd Ordinar

Grade Last Price % Change Price Change
grade A 1.25 4.17% 0.0500
CYYNF closed up 4.17 percent on Friday, August 2, 2019, on 28 percent of normal volume. The bulls were able to push the stock to a new 52-week high.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Up Up
See historical CYYNF trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week High Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Crossed Above 20 DMA Bullish 4.17%
MACD Bullish Signal Line Cross Bullish 4.17%
New 52 Week Closing High Bullish 4.17%
Pocket Pivot Bullish Swing Setup 4.17%

Older signals for CYYNF ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand name for human therapeutic use in Australia. Its lead therapeutic product candidate is CYP-001, which is in Phase I clinical trial for the treatment of graft versus host disease. The company also develops products for the treatment of heart attack, asthma, acute respiratory distress syndrome, diabetic wounds, coronary artery disease, brain cancer, and critical limb ischaemia, which are in preclinical model. The company has a partnership with Monash University, Critical Care Research Group, University of Sydney, Department of Neurosurgery at Brigham and Women's Hospital - Harvard Medical School, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, and the Royal College of Surgeons Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.
Biotechnology Branches Of Biology Life Sciences Biology Stem Cells Cell Biology Cell Therapy Asthma Coronary Artery Disease Neurosurgery Mesoblast Heart Attack Brain Cancer Host Disease Stem Cell Therapies Treatment Of Graft Versus Host Disease
Is CYYNF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 1.25
52 Week Low 0.34
Average Volume 3,562
200-Day Moving Average 0.0
50-Day Moving Average 0.8088
20-Day Moving Average 0.9314
10-Day Moving Average 0.9495
Average True Range 0.0862
ADX 13.81
+DI 64.7815
-DI 34.7707
Chandelier Exit (Long, 3 ATRs ) 0.9914
Chandelier Exit (Short, 3 ATRs ) 1.0086
Upper Bollinger Band 1.1764
Lower Bollinger Band 0.6864
Percent B (%b) 1.15
BandWidth 52.608976
MACD Line 0.0661
MACD Signal Line 0.0468
MACD Histogram 0.0193
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.2500
Resistance 3 (R3) 1.2500 1.2500 1.2500
Resistance 2 (R2) 1.2500 1.2500 1.2500 1.2500
Resistance 1 (R1) 1.2500 1.2500 1.2500 1.2500 1.2500
Pivot Point 1.2500 1.2500 1.2500 1.2500 1.2500
Support 1 (S1) 1.2500 1.2500 1.2500 1.2500 1.2500
Support 2 (S2) 1.2500 1.2500 1.2500 1.2500
Support 3 (S3) 1.2500 1.2500 1.2500
Support 4 (S4) 1.2500